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Neurofibromatosis type 1 (NF1) is a hereditary tumor syndrome characterized by an
increased risk of malignant peripheral nerve sheath tumors (MPNST). Chemotherapy of
MPNST is still insufficient. In this study, we investigated whether human tumor Schwann
cells derived from NF1 associated MPNST respond to all-trans retinoic acid (ATRA). We
analyzed effects of ATRA and MEK inhibitor (MEKi) combination therapy.
Methods
MPNST cell lines S462, T265, NSF1 were treated with ATRA and MEKi U0126 and
PD0325901. We assessed cell viability, proliferation, migration, apoptosis and differentia-
tion as well as mRNA expression of RAR and RXR subtypes and ATRA target genes such
as CRABP2, CYP26A1, RARB and PDK1. We also analyzed CRABP2 methylation in cell
lines and performed immunohistochemistry of human MPNST specimens.
Results
ATRA therapy reduced viability and proliferation in S462 and T265 cells, accompanied by
differentiation, apoptosis and reduced migration. NSF1 cells which lacked RXRG expres-
sion did not respond to ATRA. We furthermore demonstrated that ATRA signaling was
functional for common targets, and that mRNA expression of CRABP2 and its targets was
raised by ATRA therapy, whereas alternative pathways via FABP5 were not induced.
Finally, combination of ATRA and MEKi demonstrated additively reduced viability of T265
and S462 cells.
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Conclusions
We observed therapeutic effects in two of three MPNST cell lines pronounced by combina-
tion therapy. These data point to a potentially successful treatment of MPNST by combined
application of ATRA and MEK inhibitors such as U0126 or PD0325901.
Introduction
Malignant peripheral nerve sheath tumors are soft tissue sarcomas that typically occur in the
setting of Neurofibromatosis type 1 (NF1) [1, 2]. NF1 is a common hereditary tumor syn-
drome with a variable clinical expression [3]. The development of MPNST is the major cause
of decreased life expectancy in NF1 patients, occuring in 8–13% of the patients over the life
span [4]. NF1 associated MPNST develop from benign precursors, so called neurofibromas,
the hallmark of the disease [5]. Whereas the first hit of the NF1 gene explains some of the clini-
cal signs, an additional loss-of-function mutation of NF1 is required for the development of
tumors, resulting in over activation of RAS signaling. NF1 associated neurofibromas exhibit
individual second NF1 hits, affecting precursor Schwann cells only [6–11]. Malignant transfor-
mation to MPNST is suggested to require accumulation of additional genetic aberrations.
Most common molecular aberrations besides NF1 inactivation are mutations in RB1, SOX9
and MET, homozygous deletion of CDKN2A, INK4A and ARF tumor suppressors and loss of
TP53 [12–16]. Although different chemotherapeutic regimens have been applied and pre-clini-
cal studies produced promising results, the outcome of patients with MPNST has not been sig-
nificantly improved over the past decades. Thus, surgical resection is a standard treatment
followed by chemotherapy. Although radiotherapy prolongs time to relapse, it does not
improve survival [17, 18].
Using proteome analysis, we recently observed differential expression of the cellular reti-
noic acid binding protein 2 (CRABP2), transgelin (SM22)/TAGLN and eukaryotic translation
initiation factor 4H (EIF4H) in subtypes of benign NF1-derived peripheral nerve sheath
tumors [19]. TAGLN was shown to be involved in NF1 associated tumor progression via
hypo-methylation and subsequent up-regulation and stimulation of MAPK signaling in
MPNST [20]. Differential expression of CRABP2 was investigated due to its role in cellular
transport of retinoic acid (RA) by our group in several NF1 derived tumors. In addition,
ATRA independent functions were described [21]. We demonstrated presence of CRABP2 in
neurofibroma derived Schwann cells, and therefore concluded that expression of CRABP2
might enable RA based therapeutic intervention in peripheral nerve sheath tumors [22–25].
Retinoic acid (RA) is a metabolic product of vitamin A, extracted from diet and stored as reti-
noid. Via binding to the retinol binding protein 4, RA is circulating through the blood and
taken up by cells to be metabolized into all-trans retinoic acid (ATRA) [26]. In the cytoplasm
ATRA binds to CRABP1 and CRABP2, whereat CRABP2 furthermore assists RA entering the
nucleus. Here, RA associates with retinoic acid receptors (RAR) and retinoid X receptors
(RXR) that bind specific genomic regions called retinoic acid response elements (RARE) to
allow transcription. The activation of ATRA mediated signaling pathways is also possible via
binding of the fatty acid binding protein 5 (FABP5) to the peroxisome-proliferator-activated
receptor (PPAR) / RXR nuclear complex. The intracellular ratio of CRABP2 and FABP5 pro-
tein expression is crucial for the activation of either of the two pathways [27]. ATRA is a regu-
lator in embryonic development, especially in patterning and neuronal differentiation and
furthermore essential for adult tissue homeostasis, neuronal plasticity and signal transduction
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of retina [28]. Due to its anti-carcinogenic activities ATRA is used in therapy and prevention
of cancer such as acute promyelocytic leukemia (APL) and acute myeloic leukemia (AML) [29,
30]. In-vitro and in-vivo effects of ATRA therapy were also seen in cervical cancer, lung cancer,
colon adenocarcinoma, breast cancer, kidney cancer, neuroblastoma, germ cell tumors, and
glioblastoma [31–36]. However, clinical use of ATRA can be hampered by retinoic acid resis-
tance. Hence, ATRA is used in combination therapy utilizing potential synergistic effects.
Administration of 13-cis RA significantly improved overall survival after consolidation therapy
of neuroblastoma in children, and patients with relapse of APL showed a lower relapse rate
when ATRA was combined with anthracycline [37, 38]. Benefits of combination therapy were
also shown for metastatic renal cell carcinoma (13-cis-RA + IFNA2) and acute myeloic leuke-
mia (ATRA + valproic acid) [39, 40]. In neuroblastoma cells, being resistant to ATRA due to
loss of the zinc finger protein ZNF423, the inhibition of the MAPK cascade restored ATRA
responsiveness. ZNF423 loss was addressed to NF1 loss that in turn was supposed to cause the
over activation of the Ras-MEK signaling pathway in these cells [41, 42].
Here, we investigated if treatment of tumor cells derived from NF1 associated MPNST
respond to ATRA therapy. We furthermore analyzed, if combination of ATRA and MEK
inhibitors (MEKi) enhance therapeutic effects. Thus, we elucidated involved signaling path-
ways and molecular mechanisms of ATRA in MPNST cells. Finally, our in-vitro data point to a
very promising therapeutic approach for human MPNST by combining ATRA and MEKi
application.
Materials and methods
Primary cell cultures and cell lines
Normal primary human and rat Schwann cells, the MCF-7 cell line and three human NF1
associated MPNST cell lines (S462, T265, NSF1) were analyzed [43–47]. MPNST cell lines
S462 and T265 were provided by VF Mautner (University of Hamburg). The NSF1 cell line
was provided by D Kaufmann (University Hospital Ulm, Germany). The MCF-7 cell line was
provided by V Senner (University Hospital Muenster, Germany). Experiments were per-
formed in cooperation with VF Mautner and were approved for these purposes by ethics com-
mittee of „A¨rztekammer Hamburg” (19.04.2011, No. WF-018/11). Normal primary rat
Schwann cells (nrSC) were provided by B Gess (University Hospital Muenster, Germany). Pri-
mary normal human Schwann Cells (nhSC) were purchased from ScienCell (HSC, California,
USA). Primary Schwann cells were cultivated in standard Dulbeccos modified eagles medium
(DMEM) containing 4.5 g/L glucose, 2 mM L-glutamine, 10% fetal bovine serum (FBS), 1 mM
sodium pyruvate and 100 U/mL penicillin/streptomycin supplemented with 0.5 mM 3-iso-
butyl-1-methylxanthine (IBMX), 10 nM β1-heregulin, 2.5 μg/mL insulin and 2.5 mg/L fungi-
zone. Culture vessels were coated with 1 mg/mL poly-L-lysine (10 min at room temperature)
and 4 μg/mL laminin/PBS (2 hours at 37˚C). Enrichment of Schwann cells was achieved by
mild trypsination and adhesion of fibroblasts to uncoated culture vessels. All primary cultures
showed a proportion of Schwann cells (versus fibroblasts) of above 95% (S100 immunostain-
ing). MPNST cell lines and the MCF-7 cell line were cultured using standard DMEM in
uncoated vessels.
Treatment of cells with ATRA and MEK inhibitors (MEKi)
ATRA (Sigma-Aldrich), MEK inhibitors U0126 (NEB) and PD0325901 (Selleckchem) were
dissolved in DMSO, aliquots were stored at -80˚C. Treatment was performed for 7 days
unless otherwise stated (three to five replicate wells per sample) (Table A in S8 Fig). Control
cells were treated with medium containing 0.1% DMSO. Medium supplemented with
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pharmaceuticals was changed every second day. Cells under treatment were protected from
light by aluminum foil. Experiments were performed in triplicates at least.
RNAi by transient transfection of siRNA
Transient transfection of siRNA (12 nM) was performed using HiPerFect reagent (Qiagen)
according to the manufacturer’s protocol. Simultaneously to transfection with specific siRNA,
a non-specific siRNA (si-scrambled) was used as control. Cells were seeded the day before
transfection.
Proliferation and migration assays
Cell proliferation and migration of cells was analyzed by xCELLigence DP system (Roche) [48,
49]. Migration and proliferation of cells were detected by measurement of impedance of
gold electrodes, that refers to “Cell Index”. Migration assays were performed in CIM-plates1
according to the manufacturer’s instructions and monitored for 24 h. For analysis of migration
after ATRA treatment, cells were pre-treated with ATRA (5 μM) / DMSO for two days before
seeding for migration analysis under treatment conditions. Cell proliferation was monitored
continuously in E-plates1 for 120 h according to the manufacturer’s instructions. All experi-
ments were performed in triplicates with 4 replicates.
Viability assay
Viability of cells was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazo-
lium bromide (MTT)-assay in 48- or 96-well plates. Cells were incubated with 0.5 g/L MTT
labelling solution / medium for 2 or 3 hours, depending on cell line, Thereafter, medium was
aspirated and cells were incubated with isopropanol for 5 min on an orbital shaker at 180 rpm.
Measurement of absorbance was performed at 560 nm and at the reference wavelength of 750
nm in a GloMax1-Multi+ Detection System (Promega).
Apoptosis (TUNEL) assay and flow cytometry
Cells treated with 5 μM ATRA (7 d) were subjected to APO-BrdU TUNEL Assay kit (Invitro-
gen) according to the manufacturer’s instructions for immune fluorescence and flow cytome-
try applications. For analysis of differentiation, cells were labeled with anti-S100 or anti-
PMP22 antibodies and Alexa Fluor 488 secondary antibodies. Cells treated similarly but
without primary antibody served as internal control. Cells were fixed in 1% ice-cold parafor-
maldehyde (PFA) and permeabilized in 70% ethanol before labeling with primary antibodies.
Labeled cells were analyzed using a BD FACS Canto II. Each flow cytometry analysis was per-
formed on 10.000 cells and experiments were performed 2–3 times.
Isolation and quantification of RNA and DNA
Total RNA from cultured cells was isolated using Gene Elute Mammalian total RNA Miniprep
Kit (Sigma) according to the provided protocol including DNase digestion with the RNase-
free DNase Set (Qiagen). Isolation of genomic DNA from cultured cells was performed using
Quick-gDNA MiniPrep Kit (Zymo Research) according to the provided protocol. Concentra-
tion of RNA and DNA was determined by using a ND-1000 spectrophotometer (NanoDrop
Technologies) using ND-1000 V3-8.4 software.
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Polymerase Chain Reaction (PCR)
CDNA was prepared from 100–500 ng of total RNA with oligo (dT) primers and High Capac-
ity cDNA-RT Kit including RNase inhibitor (Applied Biosystems) according to the manufac-
turer’s instructions. PCR was performed in a PTC-200 Peltier Thermal Cycler (MJ Research)
using the HotStarTaq DNA Polymerase Kit (Qiagen). Each preparation contained 10 x PCR
Buffer, 2 mM MgCl2, 200 μM of each dNTP (dNTP Mix, PCR Grade, Qiagen), 1 U Taq Poly-
merase, 0.4 μM of each primer (Table B in S8 Fig) and 1 μL cDNA template corresponding to
1–25 ng total RNA applied in cDNA-synthesis. Amplified cDNA fragments were separated in
agarose (1.5%, 10 μg/mL ethidium bromide) and visualized in a Gel Doc EZ Imager (BioRad).
Quantitative real-time-PCR (qRT-PCR) was performed in a StepOnePlus real time PCR sys-
tem (Applied Biosystems). Endogenous GAPDH (glyceraldehyde 3-phosphate dehydrogenase)
served as internal control. Expression levels of specific mRNA sequences were calculated rela-
tive to GAPDH levels using the ΔΔCT method described previously [50]. QRT-PCR using
TaqMan Universal Master Mix (Applied Biosystems) was performed in a total volume of
20 μL, containing 1 μL Gene Expression Assay (Applied Biosystems) or 0.4 μM of each primer
(Table C in S8 Fig) and 1 μL cDNA template. QRT-PCR using SYBR Green PCR Master Mix
(Applied Biosystems) was performed in a total volume of 15 μL, containing 0.2 μM of each
primer (Table B in S8 Fig) and 1 μL cDNA template.
Methylation analysis of the CRABP2 promoter
Sodium bisulfite treatment of DNA was performed using the EpiTect1 Fast DNA Bisulfite Kit
(Qiagen) according to manufacturer’s instructions. Primers (Tables C and D in S8 Fig) were
designed using the PyroMark Assay Design 2.0 software (Qiagen). PCR was performed using
the Maxima Probe qPCR Master Mix including Maxima Hot Start Taq DNA Polymerase
(Thermo Fisher Scientific) in a total volume of 20 μL, containing 0.5 μM of each primer. Pyro-
sequencing was performed in a PyroMark Q24 system (Qiagen) according to the manufactur-
er’s instructions, using the PyroMark Gold Q24 Reagents Kit (Qiagen). Fully methylated DNA
and un-methylated DNA were used as controls. In order to visualize successful bisulfite con-
version a T was added into the dispensation order. Quantification of CpG sites was performed
with PyroMark Q24 software (Qiagen).
Western blot analysis
To obtain whole cell protein extracts, cells were washed twice with cold PBS and lysed with
RIPA buffer containing protease inhibitors. Determination of protein concentrations was per-
formed by using the Lowry method and the DCTM Protein Assay Kit (BioRad) according to
the manufacturer’s instructions. The absorbance at 750 nm was detected in a GloMax1-Multi+
Detection System [51]. Protein samples were separated by SDS-PAGE according to the
Laemmli method at 120 V until the desired separation had been reached (1–1.5 h). To deter-
mine molecular weight of detected protein bands a prestained protein marker (Precision Plus
Protein™ Dual Color Standards, BioRad) was loaded [52]. A tank-blotting chamber (Mini
Trans Blot Cell, BioRad) was used to transfer proteins to a PVDF membrane (Roche) at 250
mA for 45 min. After transfer, the PVDF membrane was incubated with blocking solution fol-
lowed by incubation with primary antibodies (Table E in S8 Fig) overnight at 4˚C. Afterwards,
the membrane was incubated in blocking solution, containing a hrp-conjugated secondary
antibody (Table E in S8 Fig), at room temperature for 1–2 h. Finally, the membrane was incu-
bated with Luminata™ Forte Western HRP Substrate (Millipore) to quantify signals by the
Chemi Doc MP Imaging system (BioRad) using Image Lab™ software (BioRad).
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Immunohistochemistry and immunocytochemistry
Human MPNST specimens from NF1 patients and non-NF1 patients were kindly provided by
Prof. W. Paulus (Institute of Neuropathology, University Hospital Muenster, Germany). These
experiments were approved by ethics committee at „A¨rztekammer Westfalen-Lippe Mu¨n-
ster”(2007-261-f-S). Written informed consent was provided for participation. MPNST cell
pellets were frozen at -80˚C, fixed in 4% PFA and stored in 70% ethanol until paraffin embed-
ding. Hematoxylin and eosin staining (HE) of FFPE samples was performed in an automated
staining instrument Tissue Tek Glas and Prisma system (Sakura). For immunohistochemistry
of FFPE samples, slices were deparaffinised and pre-treated with target retrieval solution (pH
6.1). Immunohistochemistry was performed using the DAKO REAL™ Detection Kit (K5001)
according to the provided protocol and the automated staining instrument AutostainerLink
48 (Dako). Deparaffinised sections were incubated with primary anti-CRABP2 antibody
(Abcam ab181255, monoclonal, from rabbit, 1:100). Staining was visualized by DAB staining
followed by nuclear counterstaining with hematoxylin.
Statistical analysis
We used unpaired t-test, one-sided t-test, Wilcoxon test, Mann-Witney-U test, Kruskal-
Wallis test and Students t-test for analyses. A p-value of < 0.05 was considered to be
significant.
Results
MPNST cell lines S462 and T265 are sensitive to ATRA treatment
We investigated if MPNST cells (NSF1, S462, T265) were sensitive to ATRA treatment. We
first determined expression of RAR and RXR subtypes in MPNST cells by RT-PCR, normal
human Schwann cells and fibroblasts, since intact expression of nuclear receptors is an essen-
tial requirement for mediation of ATRA effects: All receptor subtypes were expressed in nor-
mal Schwann and MPNST cells, except of the RXRG subtype which was absent in NSF1 cells
(S1 Fig). We then investigated effects of ATRA therapy on viability at day 7 of treatment: A
dose-dependent decrease of viability was seen in T265 and S462 cells, whereas NSF1 cells did
not respond (Fig 1). Normal primary rat Schwann cells as well as ATRA sensitive MCF-7
cells were used as controls. MCF-7 cells were sensitive to treatment with ATRA, whereas nor-
mal rat Schwann cells were not (Fig 1). By pyrosequencing, we analyzed, if methylation status
of the CRABP2 promoter region influenced response to ATRA treatment. In MPNST as well
as in control cells methylation analysis of three different promoter regions of CRABP2 (S2A
Fig) did neither reveal a correlation of ATRA sensitivity with a specific methylation pattern
(S2B Fig) nor an influence of ATRA therapy on promoter methylation (S2C Fig). Neverthe-
less, expression of CRABP2 in MPNST cell lines increased with decreasing promoter
methylation.
In conclusion, a markedly reduced viability and proliferation at concentrations > 10 μM
was seen in 2/3 MPNST cell lines under ATRA treatment, indicating ATRA sensitivity in a
subset of malignant tumor derived Schwann cells.
ATRA treatment induces morphological changes and differentiation
FACS analysis was carried out to analyze potential ATRA mediated differentiation of cells.
The proportion of PMP22- and S100-positive Schwann cells after treatment was assessed (Fig
2): Expression of S100 protein increased in all MPNST cells. A reduction of PMP22 expression
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was seen in 2/3 MPNST cell lines (T265, S462). Next, morphological changes resulting from
ATRA treatment were assessed by FACS: all MPNST cell lines revealed significantly higher
mean values concerning relative cell size (forward scatter) as well as granularity (sideward scat-
ter) in treated versus untreated cells (S3 Fig).
To summarize, anti-proliferative properties of ATRA in MPNST cell lines are accompanied
by morphological changes and Schwann cell differentiation.
ATRA treatment reduces migration and induces apoptosis
To evaluate migration as a parameter for tumor invasion, we monitored MPNST cell lines
under ATRA therapy in real-time (xCELLigence system). Whereas NSF1 cells did not show
reduced migration due to ATRA therapy, a strong inhibition of migration was observed in cell
line T265 and a minor effect was seen in cell line S462 (Fig 3). To evaluate induction of apopto-
sis, we performed TUNEL staining and a FACS based TUNEL assay: Increase of apoptosis was
seen in T265 MPNST cells as the proportion of TUNEL positive cell nuclei increased in ATRA
treated cultures compared to untreated controls (S4 Fig). A FACS based TUNEL assay demon-
strated pro-apoptotic effects in 2/3 MPNST cell lines treated with ATRA: The strongest effect
was seen in S462 cells showing an increase to 374% ± 35% in fluorescence intensity compared
to untreated cells (Fig 4).
In summary, 2/3 MPNST cell lines showed reduction of migration due to ATRA treatment.
Anti-proliferative properties of ATRA on tumor Schwann cells are mediated by induction of
apoptosis.
Fig 1. ATRA therapy affects viability of MPNST cells in a dose-dependent manner. Viability of cells under ATRA treatment
was monitored by MTT assay on day 7 of treatment. T265 cells showed reduced viability at high ATRA concentrations (25 μM and
50 μM) and enhanced viability at low ATRA concentrations (5 μM and 10 μM). S462 cells demonstrated reduced viability at all
ATRA concentrations. MCF-7 cells used as control were sensitive to ATRA treatment at all concentrations. In contrast, normal rat
Schwan cells displayed no change of viability under ATRA treatment. Bars represent mean values of 3–4 repeated measurements
within each cell line.
https://doi.org/10.1371/journal.pone.0187700.g001
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ATRA therapy induces expression of target genes
To identify if ATRA signaling was functional in MPNST cell lines treated with ATRA, we ana-
lyzed expression of bona fide CRABP2 targets such as CRABP2 itself, CYP26A1 and RARB by
qRT-PCR. Promoters of these target genes contain a RARE element and are therefore induc-
ible by ATRA [53]. We found all targets to be induced in cells treated with ATRA confirming
a transcriptional activation (Fig 5). Since ATRA is known to mediate effects not only via
CRABP2 and RXR/RAR but also via FABP5 and PPAR/RXR (both reflecting opposing signal-
ing pathways), we analyzed expression of FABP5 and its signaling target PDK1. In 3 MPNST
cell lines investigated by qRT-PCR, FABP5 and PDK1 mRNA levels were not elevated (S5 Fig).
Fig 2. ATRA treatment induces expression of S100 and inhibits PMP22 expression. Flow cytometry
analysis (FACS) of S100 and PMP22 protein expression in ATRA treated MPNST cells on day 7 of treatment
(5μM). Bars indicate increase or decrease of fluorescence intensity (%) compared to untreated controls
(100%). Values represent mean values (± SD) of 2–4 repeated measurements within each cell line: T265 cells
showed an increase of 158% ± 19%, S462 cells of 71% ± 18% and NSF1 cells of 49% ± 33% (A). T265 cells
showed a reduction of PMP22 expression of 22% ± 10%, and S462 cells of 20% ± 14% (B).
https://doi.org/10.1371/journal.pone.0187700.g002
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Fig 3. ATRA treatment reduces migration in 2/3 MPNST cell lines. Migration of MPNST cells under ATRA treatment,
monitored using the xCELLigence system. Area under curve (AUC) was calculated after 16 h. Bars indicate AUC values
(mean of 3–5 repeated measurements within each cell line) compared to control cells. T265 cells (25 μM ATRA) showed
strongly reduced migration down to 37% ± 15%. A minor effect of ATRA treatment was observed in S462 cells (10 μM
ATRA) with reduced migration of 79% ± 7%. No effect on migration was observed in NSF1 cells (50 μM ATRA) (105% ±
5%) (A). Migration curves of ATRA treated T265 cells (ATRA, grey line) and untreated T265 cells (control, black line) are
demonstrated exemplarily (B).
https://doi.org/10.1371/journal.pone.0187700.g003
Fig 4. ATRA treatment induces apoptosis in T265 and S462 cells. Flow cytometry analysis (FACS) of TUNEL staining in ATRA treated MPNST
cells at day 7 (5 μM). Bars represent intensity values (mean of 2–3 repeated measurements within each cell line) compared to control cells (black bars):
Increase of TUNEL staining intensity to 127% ± 10% in T265 cells, to 374% ± 35% in S462 cells and 109% ± 3% in NSF1 cells (A). Right shift (regular
line) in fluorescence intensity compared to untreated controls (dashed line) in the FACS histogram is shown for T265, S462 and NSF1 cells (B).
https://doi.org/10.1371/journal.pone.0187700.g004
Fig 5. ATRA treatment induces expression of classical targets in MPNST. Relative mRNA expression of bona fide
ATRA targets was analyzed in MPNST cells after ATRA treatment by qRT-PCR. Bars represent levels of CRABP2,
CYP26A1 and RARB relative to untreated control cells (black line, 1-fold). All three MPNST cell lines showed induction of
the investigated targets. T265 cells showed lowest induction (CRABP2, CYP26A1, RARB) by ATRA treatment
(1.5-fold ± 0.1, 55.8-fold ± 21.1, 10.8-fold ± 3.3) whereas NSF1 cells showed highest induction of mRNAs after ATRA
treatment (57.8-fold ± 26.2, 633.0-fold ± 43.6, 24.5-fold ± 6.1) among the three MPNST cell lines. Measurements were
repeated in each cell line 3 times.
https://doi.org/10.1371/journal.pone.0187700.g005
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As CRABP2 is the major mediator of cellular ATRA response, its expression in a series of
tumor Schwann cells had been analyzed in previous studies [21]. Here we demonstrated that
Schwann cells in human MPNST (FFPE) as well as MPNST cell lines expressed CRABP2. To
conclude, ATRA signaling was shown to be functional for targets of CRABP2 mediated ATRA
signaling pathways. During ATRA therapy, mRNA expression of CRABP2 raised, whereas
alternative pathways (via FABP5 and subsequent PDK1 up-regulation) were not induced.
MEK inhibitor treatment reduces viability
We first analyzed exclusive MEKi administration. MEKi treatment is known to decrease NF1
associated overactive MAPK signaling and to restore retinoic acid sensitivity in NF1 lacking
neuroblastoma cells [41, 42]. Therefore, we determined the effects of MEKi U0126 and
PD0325901 treatment on viability of cells (MTT-assay): A dose dependent response was
achieved by treatment with MEKi U0126 in MPNST cell lines T265, S462, and NSF1 (Fig 6A),
although effectiveness was much lower in NSF1 cells. Treatment of tumor cells with MEKi
Fig 6. MEK inhibition reduces viability of MPNST cells. Viability of MPNST cells under MEKi treatment
was monitored by MTT. MPNST cells were treated with different doses of MEKi U0126 (upper panel) or
PD0325901 (lower panel). T265 cells and S462 cells highly responded to MEKi treatment with reduced
viability, whereas NSF1 cells did not show enhanced sensitivity to MEKi treatment, compared to untreated
control cells (black bars). Maximum reduction of viability was achieved at 10 μM of U0126 and 1 μM of
PD0325901 (reduction down to 53% ± 7% and 2% ± 1% in T265 cells, and 59% ± 7% and 19% ± 11% in S462
cells) (mean value of 3–5 measurements in each cell line (A). Relative ERK-P expression in T265 cells after
MEKi treatment was analyzed. Western blots of ERK-P, ERK and GAPDH antibodies are demonstrated
exemplarily for T265 cells after treatment with 10 nM PD0325901 (+) compared to untreated cells (-). T265
cells treated with MEKi demonstrated strongly reduced phosphorylated ERK level (grey bar, 0.32-fold ±
0.11-fold) compared to untreated control cells (black bar, 1.00-fold ± 0.25-fold). PD0325901 treatment did not
affect total ERK level in treated (grey bar, 1.04-fold ± 0.07-fold) versus untreated T265 cells (black bar,
1.00-fold ± 0.11-fold) (mean value of 3 repeated measurements).
https://doi.org/10.1371/journal.pone.0187700.g006
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PD0325901 revealed a reduction of viability in T265 and S462 cells at lower doses, whereas
NSF1 cells did not show marked sensitivity (Fig 6A). At 1000 nM viability of T265 cells was
reduced to 2% ± 1% and viability of S462 cells was reduced to 19% ± 11%. NSF1 cells showed a
slight reduction to 67% ± 10%.
To substantiate downstream effects of MEKi, we analyzed expression of phosphorylated
ERK (ERK-P). Elevated levels of Ras-GTP and activation of ERK is typical for NF1 associated
MPNST. In principal, ERK phosphorylation is mediated by MEK1/2, which can be inhibited
by MEKi such as PD0325901. Since reduced ERK-P expression has already been shown for
human S462 MPNST cells after treatment with PD0325901 [54] we here tested ERK-P in T265
cells as a proof of principle for our experiments: ERK1/2 phosphorylation was significantly
reduced in treated versus untreated T265 MPNST cells (Fig 6B). Additionally, we analyzed a
transcriptional co-activator for retinoic acid receptors, ZNF423, which has been described to
be lost in human NF1 lacking neuroblastoma cells. Absence of ZNF423 was demonstrated to
explain decreased retinoic acid response which was restored by MEKi treatment [41, 42]. In
contrast to these findings, we did not observe any induction of ZNF423 after PD0325901 treat-
ment in all NF1 deficient MPNST cell lines. Unexpectedly, ZNF423 levels decreased under
PD0325901 administration in T265 and NSF1 cells (S6 Fig).
To summarize, MEKi treatment reduced viability in 2/3 MPNST cell lines and was shown
to be functional since ERK1/2 phosphorylation was reduced. Contrarily to previous reports,
ZNF423 levels decreased or were not affected at all by MEKi treatment.
ATRA administration boosts impaired viability resulting from MEKi
therapy
Wecombined ATRA and MEKi treatment. Compared to monotherapy, combined therapy
revealed a significant reduction of viability of T265 and S462 cells in an additive manner using
both U0126 and PD0325901 (Fig 7). For example, administration of 10 nM PD0325901 and
10 μM ATRA reduced viability of T265 cells to 53% ± 8%, compared to 79% ± 7% under
ATRA monotherapy or 81% ± 8% under MEKi monotherapy. NSF1 cells were not sensitive to
mono- or combination therapy. Finally, we examined CRABP2,CYP26A1 and RARB gene
expression after mono- and combination therapy by qRT-PCR. Bona fide targets of ATRA-
mediated signaling were induced in all MPNST cell lines, both under mono- and under combi-
nation therapy. Here, additive effects due to combination treatment were not seen (S7 Fig).
In conclusion, combined treatment of ATRA and MEKi induced expression of bona fide
targets of ATRA mediated signaling such as CRABP2,CYP21A1, and RARB. The combination
of ATRA and MEKi U0126 or PD0325901 provokes additive effects on reduced viability of
T265 and S462 cells, suggesting a new and potentially successful therapeutic option for
MPNST.
Discussion
MPNST display aggressive and invasive growth and an early onset of metastasis [42]. Patients
have a poor prognosis with 5 year survival rates between 26–60% [43–46]. About 40% of
MPNST are associated with NF1, warranting regular checkup in NF1 patients with a high
tumor load [47]. In our study we could demonstrate that in-vitro combination of ATRA and
MEKi reduces proliferation of tumor Schwann cells derived from NF1 associated MPNST.
Reduced proliferation by ATRA administration alone, seen in MPNST cell lines T265 and
S462, was markedly intensified by combination with MEKi U0126 or PD0325901. MEKi treat-
ment alone reduced viability in T265 and S462 MPNST cells accompanied by reduced ERK1/2
phosphorylation. Further studies should address if these combined effects are also achieved at
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doses of ATRA that are used for clinical therapy such as 1–2 μM. Compared to benign neurofi-
bromas MAPK signaling is further elevated in MPNST cells which contributes to their aggres-
sive malignancy. MAPK inhibition seems to further repress tumor cell survival combined with
ATRA treatment. Our results indicate a therapeutic potential of ATRA. Combination with
MEKi constitutes a novel approach for NF1 associated malignant peripheral nerve sheath
tumors.
Interestingly, ATRA was shown to display anti-proliferative properties by induction of apo-
ptosis, differentiation and morphologic changes and by reduction of cell migration (Table 1).
ATRA sensitivity remarkably differed between the cell lines with most pronounced effects in
S462 and T265 cells, which warrant further investigations. We demonstrated that ATRA
induces moderate anti-proliferative effects in MPNST cells T265 and S462 via apoptosis. These
findings are in concordance with other studies describing induction of apoptosis via increased
expression of pro-apoptotic genes such as CASP7 and CASP9 in MCF-7 cells. Interestingly,
CASP9 contains a functional RARE which implicates this gene to be a direct target of
CRABP2-mediated ATRA signaling [33]. Reduced viability of MPNST cells treated with
ATRA was accompanied by reduced migration properties and signs of differentiation. The lat-
ter was also recently shown for neuroblastoma cells, underlining that induction of differentia-
tion and pro-apoptotic signaling by retinoic acid are the reasons for its general usage in
oncology and dermatology [55, 56]. We think that apoptosis that we measured at day 7 after
treatment may not largely influence migration of cells in our assay which was performed
within the first 24h after treatment. To completely rule out an influence an apoptosis on migra-
tion behavior an apoptosis inhibitor might be applied when measuring migration of MPNST
cells in further experiments. In fact, in agreement with our results, an earlier study described
Fig 7. Combined ATRA and MEKi treatment adds reduced viability. Relative viability of MPNST cells after combination
therapy (day 5) was assessed by MTT assay. MPNST cells were treated with ATRA (light grey) and MEKi (dark grey) alone or in
combination (striped). PD0325901 combination treatment is shown in the upper panel, U0126 combination treatment in the lower
panel. A significant reduction of viability in the combination therapy group was found for T265 cells and S462 cells with both
inhibitors, compared to mono-treated cells. Bars represent mean values of repeated (3–5 times) measurements in each cell line).
NSF1 cells displayed no additive effects due to combination-therapy, neither with PD0325901 nor with U0126, as well as a very
weak response to monotherapy.
https://doi.org/10.1371/journal.pone.0187700.g007
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induction of morphological changes in MPNST cells from a spindle-cell to an epitheloid-cell
phenotype using ATRA. [57]
In our hands, NSF1 MPNST cells demonstrated resistance to ATRA therapy since no major
effects were seen regarding viability, proliferation, apoptosis and migration under ATRA treat-
ment. However, loss of RXRG expression identified in NSF1 cells seems not to explain resis-
tance to ATRA entirely, due to the fact that we demonstrated these cells to highly upregulate
CRABP2 and its downstream targets after ATRA administration (Table 1). In contrast, embry-
onic stem cells lacking RARG fail transcriptional activation of ATRA target genes such as
CRABP2 and CYP26A1 after ATRA treatment [58]. Although little is known about the role of
RXRG in Schwann cells, absent expression of RXRG in NSF1 cells may contribute to resistance
to ATRA therapy through other mechanisms. Similarly, a defective RARB promoter was dem-
onstrated to lead to partial insensitivity of thyroid cancer cells [59, 60]. A general pre-therapeu-
tic testing of elements necessary for a functional retinoic acid transcription complex may
uncover ATRA resistant MPNST subtypes prior to therapy. Another explanation for resistance
of MPNST to ATRA treatment would include CRABP2 promoter methylation as a determi-
nant of RA effects [56, 61]. We expected CRABP2methylation being causal in those cells that
exhibited worse response to ATRA. Although we covered three different promoter regions
between -445 up to +370 relative to TSS, we failed to determine a correlation between ATRA
sensitivity and CRABP2 promoter methylation as it was shown for other cancer cells such as
for gliomas, medulloblastomas, Wilms tumors and pancreatic adenocarcinomas [56, 61–63].
Since CRABP2 mediates functions of ATRA, we investigated CRABP2 expression and
response to RA signaling in-vitro in detail. Bona fide targets of CRABP2-mediated ATRA sig-
naling such as CRABP2,RARB, and CYP21A1were demonstrated to be up-regulated due to
ATRA treatment in all MPNST cell lines (Table 1) as it was shown in other studies for mouse
embryonic carcinoma cells, for COS-7 monkey fibroblast cells as well as for head and neck
squamous cell carcinoma cells [64–66]. Although ATRA treatment induced common targets
in MPNST cell lines, functional effects of treatment were not seen in NSF1 cells, pointing to
other resistance mechanisms as discussed above. Since ATRA is able to induce also opposing
effects via FABP5 [27], we furthermore investigated mRNA of its target PDK1 in MPNST cells.
Table 1. Therapeutic pattern and gene expression profiles in MPNST cells. Relative expression, functional effects and promoter methylation is depicted
in a semi-quantitative manner applying the following score: three symbols—highest, two symbols—medium, one symbol—low, dash—no, induction/reduc-
tion/expression among the three MPNST cell lines.
T265 S462 NSF1
CRABP2 promoter methylation - +++ +
RAR (A, B, G) and RXR (A, B, G) mRNA expression all expressed all expressed RXRG not expressed
ATRA treatment
CYP26A1 / RARB / CRABP2 mRNA level " "" """
PDK1 mRNA level - - -
Viability ## ### -
Proliferation ## ### -
Migration ### # -
Apoptosis "" """ -
MEKi treatment
Viability ### ## #
Combination treatment
Viability ### ### -
Sensitivity towards treatment +++ +++ -
https://doi.org/10.1371/journal.pone.0187700.t001
Combined therapy of MEK inhibitors and ATRA in NF1 associated MPNST
PLOS ONE | https://doi.org/10.1371/journal.pone.0187700 November 13, 2017 13 / 20
We demonstrated that expression levels of PDK1 were not affected under ATRA treatment in
all MPNST cell lines. The ratio of FABP5/CRABP2 was previously demonstrated to be associ-
ated with ATRA resistance in gliomas, with prognostic behavior in pancreatic ductal adeno-
carcinoma cell lines, with activation of PPAR instead of RAR in a breast cancer mouse model
and with tumor grade and prognosis in breast cancer [63, 67–69]. In our study, we verified
that FABP5 level did not interfere with ATRA sensitivity in MPNST, like in other human can-
cers. Thus, CRABP2 is not only necessary to enable ATRA signaling but is the prevalent medi-
ator compared to opposing signaling pathways in MPNST. To underline these findings, we
were able to detect expression of CRABP2 in a series of human MPNST FFPE specimens and
in all three MPNST cell lines. Thus, expression of CRABP2 in tumor Schwann cells makes
these cells principally suitable for ATRA treatment.
In a previous study the transcriptional co-activator ZNF423 was suppressed in neuroblas-
toma cells lacking NF1 due to overactive MAPK cascade signaling, finally leading to ATRA
resistance [41]. Inhibiting the cascade by MEKi treatment led to ATRA response [42]. Thus, a
mutual factor of ATRA and Ras signaling was identified by this group. Although in our study
ATRA and MEKi treatment induced enhanced therapeutic effects, this was not attributed to
changes of ZNF423mRNA levels. ZNF423 levels did not correlate at all with ATRA sensitivity
of MPNST. This is in obvious contrast to previous studies and demonstrates other mecha-
nisms involved in MPNST cells compared to neuroblastoma cells.
Our data point to a potentially successful treatment of MPNST by combined application of
ATRA and MEK inhibitors such as U0126 or PD0325901. In further experiments, effects other
than reduced cellular proliferation of this combination therapy should be monitored to under-
stand the biological impact. This therapeutic strategy utilizes two specific characteristics of
NF1 associated MPNST—first, over active MAPK signaling and second, CRABP2 expression
of these tumors. Additive effects on reduced viability were successfully demonstrated in two
MPNST cells lines, whereas a probable resistance mechanism in ATRA/MEKi resistant NSF1
cells needs further investigations. Since NF1 deficient tumor cells are generally characterized
by over-activation of Ras and, as we demonstrated, by CRABP2 expression, the combination
of MEKi and ATRA seems to be a promising new approach, necessarily to be validated in ani-
mal experiments.
Supporting information
S1 Fig. Expression profile of nuclear receptors. MPNST cell lines (NSF1, S462, T265), nor-
mal human fibroblasts (nFib) and normal human Schwann cells (nhSC) were analyzed by
PCR. Negative control conditions are labelled with H2O. All six receptor subtypes were dem-
onstrated to be expressed on mRNA level in each of the analyzed cell types, except the RXRG
receptor that was not present in NSF1 cells (one representative image is shown of n = 3).
(PDF)
S2 Fig. Genomic structure of the CRABP2 gene (S2A), methylation analysis of CRBP2 pro-
moter by prosequencing (S2B), and CRABP2 promoter methylation profiles of MPNST
cells under ATRA treatment (S2C). S2A: Schematic map of the CRABP2 gene, including
5‘CpG island and its relative orientation to the transcription start point (exons = filled boxes,
UTR = open boxes, transcription initiation site = +1). The 129 single CpG sites of the whole
CpG island are illustrated as single vertically dashes in the lower part. Analyzed sequences
within the CpG island are indicated below the single CpG sites. S2B: Methylation profiles of
normal human Schwann cells (nhSC) and MPNST cell lines were demonstrated for three ana-
lyzed regions of the CpG island, with mean CpG methylation in % for each CpG (SD < 7% is
not shown). Exact number of each CpG site analyzed was depicted in the bottom line (grey
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box). Methylation profiles differed highly between the MPNST cell lines. T265 cell line showed
similar methylation pattern (max. methylation per CpG site < 16.9%) to nhSC control cells.
S462 cells demonstrated high methylation status for all CpG sites (mean methylation of
71.0%). The NSF1 cell line showed a highly variable methylation pattern with methylation sta-
tus ranging from 3.4% to 72.0% for single CpG sites (mean, n = 4). S2C: No differences were
observed in relative methylation status (%) of all analyzed CpG sites in ATRA treated MPNST
cells compared to untreated cells (mean ± SD, n = 4).
(PDF)
S3 Fig. Flow cytometry analysis of MPNST cell lines treated with ATRA. Relative increase
of size (FSC, light grey) and granularity (SSC, dim grey) is given in % compared to untreated
controls (0%). Relative cell size was increased by 16% in NSF1 cells, 14% in S462 cells and 6%
in T265 cells. Granularity was increased by 14% in T265 cells, 22% in S462 cells and 39% in
NSF1 cells (p<0.05, one-sided t-test, mean + SD, n = 3).
(PDF)
S4 Fig. Apoptosis (TUNEL) staining in ATRA treated T265 cells. Merged images of DAPI
and TUNEL are depicted for MPNST cell line T265. Number of TUNEL positive cell nuclei is
clearly increased in ATRA treated cultures as compared to controls (exemplarily shown images
of immunocytochemistry staining).
(PDF)
S5 Fig. Relative mRNA levels in MPNST cells by qRT-PCR. PDK1 expression was not
affected in MPNST cells treated with ATRA (grey bars) as compared to untreated cells (black
line). FABP5 expression was not affected by ATRA treatment in S462 cells and NSF1 cells,
and only slightly induced in T265 cells, as compared to untreated control cells (black line, 1)
(mean + SD, n = 3).
(PDF)
S6 Fig. Relative mRNA expression of CRABP2 and ZNF423 after MEKi treatment in
MPNST cells by qRT-PCR. MPNST cells were incubated with different doses of PD0325901.
CRABP2 expression was found to be induced at all concentrations in T265 and S462 cells
(grey bars) compared to untreated control cells (black line). NSF1 cells showed decreased
CRABP2 level at 1 nM and 10 nM PD0325901, but increased level at 1000 nM. ZNF423 expres-
sion was reduced in T265 cells in a dose-dependent manner but was not affected in S462 cells
at all concentrations. Reduced ZNF423 levels were also found in NSF1 cells. Relative mRNA
level were not determined in T265 cells at 1000 nM PD0325901, since almost no alive cells
were present (n.d. = not determined) (mean + SD, n = 3).
(PDF)
S7 Fig. Relative mRNA expression in MPNST cell lines after combined treatment with
ATRA and PD by qRT-PCR. MPNST cells were treated with ATRA and MEKi PD0325901
alone or with a combination (light colored, dark colored and striped colored bars, respectively)
(2 d). CRABP2, CYP26A1 and RARB mRNA expression were induced in all MPNST cell lines.
Mild additive effects on induction of CRABP2 mRNA expression via combined therapy were
observed in T265 and NSF1 cells compared to mono-therapy (mean + SD, n = 3).
(PDF)
S8 Fig. Concentrations, primer and antibody specifications. Concentrations of pharmaceu-
tical agents used for combination treatment (Table A). Primer sequences for RT-PCR
(Table B). Primer sequences used for bisulfite-sequencing (Table C). Primer sequences used
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for amplification of bisulfite converted DNA (Table D). Specifications of antibodies used for
western blot analysis (Table E).
(PDF)
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